Medicine's Daniel Spratt calls new prostate cancer biomarker a milestone

Biomarker a ‘true milestone’ in guiding hormone therapy for recurrent prostate cancer

Healio: Daniel Spratt, professor of radiation oncology at the School of Medicine, said, “We have been working for over a decade trying to solve this important unmet need, trying to develop a predictive biomarker to enable the personalized use of hormone therapy.”